Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

GT Biopharma (GTBP) Interest Expenses (2016 - 2021)

GT Biopharma (GTBP) has disclosed Interest Expenses for 12 consecutive years, with $22000.0 as the latest value for Q4 2021.

  • On a quarterly basis, Interest Expenses rose 100.37% to $22000.0 in Q4 2021 year-over-year; TTM through Dec 2021 was $718000.0, a 259.0% increase, with the full-year FY2025 number at $127000.0, changed N/A from a year prior.
  • Interest Expenses was $22000.0 for Q4 2021 at GT Biopharma, down from $696000.0 in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $4.7 million in Q2 2020 to a low of -$6.0 million in Q4 2020.
  • A 5-year average of $925625.0 and a median of $813500.0 in 2020 define the central range for Interest Expenses.
  • Peak YoY movement for Interest Expenses: tumbled 92.39% in 2017, then skyrocketed 872.44% in 2020.
  • GT Biopharma's Interest Expenses stood at $135000.0 in 2017, then soared by 731.85% to $1.1 million in 2018, then crashed by 422.44% to -$3.6 million in 2019, then tumbled by 66.45% to -$6.0 million in 2020, then soared by 100.37% to $22000.0 in 2021.
  • Per Business Quant, the three most recent readings for GTBP's Interest Expenses are $22000.0 (Q4 2021), $696000.0 (Q1 2021), and -$6.0 million (Q4 2020).